Absci Q3 Revenue Misses by Half; Hair-Loss Data Readout Set for December
ABSI has more than doubled off its 52-week low of $2.24.
Summary
Absci's Q3 revenue of $0.3 million missed the $727.1 thousand estimate and the net loss widened to $33.3 million, but $173.7 million in cash funds operations into the second half of 2028. The next hard event is 13-week interim ABS-201 proof-of-concept data in pattern hair loss, expected December 2026.
Key Events · Earnings and Guidance · ABSI
-
Q3 Revenue Misses Consensus by Half
Revenue was $0.3 million versus $0.4 million a year ago and an IBES estimate of $727.1 thousand; net loss widened to $33.3 million from $28.7 million.
-
Cash Funds Operations Into 2H 2028
Cash, cash equivalents and marketable securities were $173.7 million at September 30, 2026, down from $201.1 million at June 30, 2026, with runway guided into the second half of 2028.
-
ABS-201 Hair-Loss Data Due December
13-week interim proof-of-concept data from the HEADLINE trial in pattern hair loss is anticipated in December 2026, with full 26-week data in early 2027.
-
Endometriosis Phase 2 Details Outlined
The planned STORYLINE Phase 2 trial would enroll approximately 150 patients across 10 or more countries, with initiation anticipated mid-2027.
Analysis · ABSI · Industrial Applications And Services
Revenue of $0.3 million came in well below the $727.1 thousand consensus, and the net loss widened to $33.3 million from $28.7 million a year ago as R&D spending climbed to $23.6 million. What offsets the miss is a $173.7 million cash pile that funds operations into the second half of 2028, so near-term financing pressure is not the issue. The real swing factor is the 13-week interim proof-of-concept data for ABS-201 in pattern hair loss, now guided to December 2026, with full 26-week data in early 2027 — that readout, not this quarter's revenue, will decide the stock.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABSI was trading at $9.85 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $2.24 to $12.54. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.